OncoSec Medical (FRA:ONMA) Change In Inventory : €0.00 Mil (TTM As of Jan. 2023)

View and export this data going back to 2015. Start your Free Trial

What is OncoSec Medical Change In Inventory?

OncoSec Medical's change in inventory for the quarter that ended in Jan. 2023 was €0.00 Mil. It means OncoSec Medical's inventory stayed the same from Oct. 2022 to Jan. 2023 .

OncoSec Medical's change in inventory for the fiscal year that ended in Jul. 2022 was €0.00 Mil. It means OncoSec Medical's inventory stayed the same from Jul. 2021 to Jul. 2022 .

OncoSec Medical's Total Inventories for the quarter that ended in Jan. 2023 was €0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

OncoSec Medical Change In Inventory Historical Data

The historical data trend for OncoSec Medical's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoSec Medical Change In Inventory Chart

OncoSec Medical Annual Data

Trend

Jul13

Jul14

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Change In Inventory

Get a 7-Day Free Trial

OncoSec Medical Quarterly Data
	Apr18	Jul18	Oct18	Jan19	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23
Change In Inventory	Get a 7-Day Free Trial															-	-	-	-	-

OncoSec Medical Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Jan. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

OncoSec Medical (FRA:ONMA) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

OncoSec Medical's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	0	/	0	*	365 / 4
	=	N/A

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

OncoSec Medical's Inventory Turnover for the quarter that ended in Jan. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	0
	=	N/A

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

OncoSec Medical's Inventory to Revenue for the quarter that ended in Jan. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	0
	=	N/A

OncoSec Medical Change In Inventory Related Terms

Thank you for viewing the detailed overview of OncoSec Medical's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

OncoSec Medical (FRA:ONMA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoSec Medical Inc (FRA:ONMA) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

ONCSQ:USA

Address

24 North Main Street, Pennington, NJ, USA, 08534

Website

https://www.oncosec.com

OncoSec Medical Inc is a healthcare sector company. It is focused on designing, developing and commercializing gene therapies, therapeutics, and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple-negative breast cancer.

OncoSec Medical (FRA:ONMA) Headlines

No Headlines